Vericel Corp
NASDAQ:VCEL

Watchlist Manager
Vericel Corp Logo
Vericel Corp
NASDAQ:VCEL
Watchlist
Price: 58.75 USD 0.22% Market Closed
Market Cap: 2.9B USD
Have any thoughts about
Vericel Corp?
Write Note

Gross Margin
Vericel Corp

71.5%
Current
68%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
71.5%
=
Gross Profit
162.1m
/
Revenue
226.8m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Vericel Corp
NASDAQ:VCEL
2.9B USD
71%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
67%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
60%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
86%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
78%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
34.3B EUR
89%
Country US
Market Cap 2.9B USD
Gross Margin
71%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 320.1B USD
Gross Margin
67%
Country US
Market Cap 147.4B USD
Gross Margin
60%
Country US
Market Cap 119.4B USD
Gross Margin
86%
Country US
Market Cap 113.8B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.4B AUD
Gross Margin
52%
Country US
Market Cap 82.6B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.3B EUR
Gross Margin
89%
No Stocks Found

Vericel Corp
Glance View

Market Cap
2.9B USD
Industry
Biotechnology

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 281 full-time employees. The firm is focused on therapies for the sports medicine and severe burn care markets. The company markets two autologous cell therapy products in the United States, which include MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA). Its NexoBrid, is a registration-stage, topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.

VCEL Intrinsic Value
29.46 USD
Overvaluation 50%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
71.5%
=
Gross Profit
162.1m
/
Revenue
226.8m
What is the Gross Margin of Vericel Corp?

Based on Vericel Corp's most recent financial statements, the company has Gross Margin of 71.5%.